Recent Research Analysts’ Ratings Changes for LENZ Therapeutics (LENZ)

A number of research firms have changed their ratings and price targets for LENZ Therapeutics (NASDAQ: LENZ):

• 10/27/2025 – LENZ Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $56.00 price target on the stock.
• 10/22/2025 – LENZ Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/20/2025 – LENZ Therapeutics had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $50.00 price target on the stock, up previously from $40.00.
• 10/10/2025 – LENZ Therapeutics had its price target raised by analysts at Piper Sandler to $67.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – LENZ Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – LENZ Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.